A patient on a GLP-1 receptor agonist (liraglutide) requires dose adjustment. GLP-1R agonists stimulate insulin secretion via a glucose-dependent mechanism. The molecular explanation for this glucose-dependency is:

• A GLP-1 directly opens ATP-sensitive potassium channels only when blood glucose is low
• B GLP-1 inhibits alpha-cell glucagon secretion, which secondarily reduces gluconeogenesis-driven hyperglycemia
• C GLP-1 amplifies glucose-stimulated insulin secretion by increasing cAMP/PKA and cAMP/Epac2 signaling, which only triggers exocytosis when the beta cell is already depolarized by glucose ✓
• D GLP-1 induces GLUT2 expression in beta cells increasing glucose sensing at any glucose level

Explanation

GLP-1 receptor agonism increases intracellular cAMP, activating both PKA (protein kinase A) and Epac2 (exchange protein directly activated by cAMP). These pathways potentiate insulin granule exocytosis BUT only amplify the process when the beta cell is already depolarized — which happens only when glucose-driven ATP production closes KATP channels and triggers action potentials. This explains the glucose-dependency: at low blood glucose, there is insufficient ATP to close KATP channels, so GLP-1 signaling does not trigger exocytosis, making hypoglycemia with GLP-1 agonist monotherapy rare. The mechanism is enhancement/amplification, not initiation.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.